Morikawa Mitsuhiro, Goi Takanori
First Dept. of Surgery, University of Fukui.
Gan To Kagaku Ryoho. 2025 Aug;52(8):567-571.
Pseudomyxoma peritonei(PMP)is rare disease, but in other countries, cytoreductive surgery(CRS)plus hyperthermic intraperitoneal chemotherapy(HIPEC)is the standard treatment, but in Japan it is not covered by insurance and is only being treated at a few institutions. In 2021, Japanese Society of Peritoneal Malignancy issued Clinical Practice Guideline for Peritoneal Malignancy, in which CRS+HIPEC was weakly recommended, but few new centres have started this treatment as it is not covered by insurance. We have been performing CRS+HIPEC for PMP and peritoneal dissemination of colorectal cancer since 1990, and hope to expand this treatment by reporting on our methods and outcomes.
腹膜假黏液瘤（PMP）是一种罕见疾病，但在其他国家，细胞减灭术（CRS）联合腹腔热灌注化疗（HIPEC）是标准治疗方法，然而在日本，该治疗未纳入医保，仅在少数机构开展。2021年，日本腹膜恶性肿瘤学会发布了腹膜恶性肿瘤临床实践指南，其中对CRS+HIPEC给出了弱推荐，但由于未纳入医保，很少有新的中心开展这种治疗。自1990年以来，我们一直对PMP和结直肠癌腹膜转移患者实施CRS+HIPEC治疗，希望通过报告我们的治疗方法和结果来推广这种治疗。
